AKTS

Aktis Oncology, Inc.

$19.21-0.88 (-4.38%)
Price
MA20
Insider buy
Insider sell
Loading chart...
🤖 AI InsightHaiku 4.5

Aktis Oncology, Inc. (AKTS) is a publicly traded company with 1 insider transaction disclosed via SEC Form 4 in the past 90 days, involving 1 unique insider. All data below is sourced directly from public SEC EDGAR Form 4 filings.

Latest Insider Transactions

Showing 10 of 27 transactions (past 365 days)

AKTS
Director
Award
$685K
Gormley Glenn37,866 shares @ $18.09
Filed 2026-04-16Trade 2026-04-15
AKTS
Director
Conversion
$0
Foley Todd597,391 shares @ $0.00
Filed 2026-01-14Trade 2026-01-12
AKTS
10% Owner
Conversion
$0
Mpm Bioventures 2018, L.P.1,314,262 shares @ $0.00
Filed 2026-01-14Trade 2026-01-12
AKTS
10% Owner
Conversion
$0
Mpm Bioventures 2018, L.P.5,914,197 shares @ $0.00
Filed 2026-01-14Trade 2026-01-12
AKTS
10% Owner
Conversion
$0
Mpm Bioventures 2018, L.P.1,577,119 shares @ $0.00
Filed 2026-01-14Trade 2026-01-12
AKTS
Director
Purchase
$405.8K
Kim Helen Susan22,545 shares @ $18.00
Filed 2026-01-12Trade 2026-01-12
AKTS
10% Owner
Conversion
$0
Vida Ventures Ii, Llc4,859,370 shares @ $0.00
Filed 2026-01-12Trade 2026-01-12
AKTS
Director
Conversion
$0
Ecor1 Capital, Llc202,862 shares @ $0.00
Filed 2026-01-12Trade 2026-01-12
AKTS
10% Owner
Purchase
$14.6M
Vida Ventures Ii, Llc812,455 shares @ $18.00
Filed 2026-01-12Trade 2026-01-12
AKTS
Director
Conversion
$0
Ecor1 Capital, Llc128,506 shares @ $0.00
Filed 2026-01-12Trade 2026-01-12

Want to see more transactions?

Sign up for free to unlock more insider transactions and create watchlists.

Cluster Buy Signals →All Insider Signals →Top Insider Buying →